APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biologics and Biosimilars

A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.

A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.

Selected research

Market Structure

Global Biologics and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

25 December 2025195 pages

Choose your research edition.

Industry ResearchBiologics and Biosimilars Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Biologics and Biosimilars Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Biologics and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biologics and Biosimilars Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Biologics and Biosimilars Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.

A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.

The major global manufacturers of biologics and biosimilars are Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, Sansheng Pharmaceuticals, Changchun Gaoxin, CITICS Guojia, Baitai Biotech, Sijin Biotech, Cinda Biotech, Tonghua Dongbao, Ganli and Union Pharmaceuticals, etc. Roche, Amgen and AbbVie are the top three, with a combined market share of about 37%.

Read the full market overview

This report provides an overview of the global Biologics and Biosimilars market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biologics and Biosimilars and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biologics and Biosimilars sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Biologics and Biosimilars market size, projected growth trends, production technologies, key applications, and end-use industries.

Biologics and Biosimilars Segment by Company

Roche

Amgen

AbbVie

Sanofi-Aventis

Johnson & Johnson

Pfizer

Novo Nordisk

Eli Lilly

Novartis

Merck

3sbio

Changchun High Tech

CP Guojian

Biotech

Gelgen

Innovent

Dong Bao

Ganlee

United Laboratories

Biologics and Biosimilars Segment by Type

Monoclonal Antibodies

Interferon

Erythropoietin

Insulin

Vaccines

Others

Biologics and Biosimilars Segment by Application

Tumor

Diabetes

Cardiovascular

Hemophilia

Others

Biologics and Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Biologics and Biosimilars market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Biologics and Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Biologics and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Biologics and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Biologics and Biosimilars Industry Trends Table 2. Biologics and Biosimilars Industry Drivers Table 3. Biologics and Biosimilars Industry Opportunities and Challenges Table 4. Biologics and Biosimilars Industry Restraints Table 5. Global Biologics and Biosimilars Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Biologics and Biosimilars Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Biologics and Biosimilars Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Biologics and Biosimilars Sales Market Share by Manufacturers Table 9. Global Biologics and Biosimilars Average Sales Price (USD/Unit) of Manufacturers (2021-2026) Table 10. Global Biologics and Biosimilars Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Biologics and Biosimilars Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Biologics and Biosimilars Manufacturers, Product Type & Application Table 13. Global Biologics and Biosimilars Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Biologics and Biosimilars by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Monoclonal Antibodies Table 17. Major Manufacturers of Interferon Table 18. Major Manufacturers of Erythropoietin Table 19. Major Manufacturers of Insulin Table 20. Major Manufacturers of Vaccines Table 21. Major Manufacturers of Others Table 22. Global Biologics and Biosimilars Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Biologics and Biosimilars Sales by Type (2021-2026) & (K Units) Table 24. Global Biologics and Biosimilars Sales by Type (2027-2032) & (K Units) Table 25. Global Biologics and Biosimilars Sales Market Share by Type (2021-2026) Table 26. Global Biologics and Biosimilars Sales Market Share by Type (2027-2032) Table 27. Global Biologics and Biosimilars Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global Biologics and Biosimilars Revenue by Type (2021-2026) & (K Units) Table 29. Global Biologics and Biosimilars Revenue by Type (2027-2032) & (K Units) Table 30. Global Biologics and Biosimilars Revenue Market Share by Type (2021-2026) Table 31. Global Biologics and Biosimilars Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Tumor Table 33. Major Manufacturers of Diabetes Table 34. Major Manufacturers of Cardiovascular Table 35. Major Manufacturers of Hemophilia Table 36. Major Manufacturers of Others Table 37. Global Biologics and Biosimilars Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Biologics and Biosimilars Sales by Application (2021-2026) & (K Units) Table 39. Global Biologics and Biosimilars Sales by Application (2027-2032) & (K Units) Table 40. Global Biologics and Biosimilars Sales Market Share by Application (2021-2026) Table 41. Global Biologics and Biosimilars Sales Market Share by Application (2027-2032) Table 42. Global Biologics and Biosimilars Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 43. Global Biologics and Biosimilars Revenue by Application (2021-2026) & (K Units) Table 44. Global Biologics and Biosimilars Revenue by Application (2027-2032) & (K Units) Table 45. Global Biologics and Biosimilars Revenue Market Share by Application (2021-2026) Table 46. Global Biologics and Biosimilars Revenue Market Share by Application (2027-2032) Table 47. Global Biologics and Biosimilars Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 48. Global Biologics and Biosimilars Sales by Region (2021-2026) & (K Units) Table 49. Global Biologics and Biosimilars Sales Market Share by Region (2021-2026) Table 50. Global Biologics and Biosimilars Sales Forecasted by Region (2027-2032) & (K Units) Table 51. Global Biologics and Biosimilars Sales Forecasted Market Share by Region (2027-2032) Table 52. North America Biologics and Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. North America Biologics and Biosimilars Sales by Country (2021-2026) & (K Units) Table 54. North America Biologics and Biosimilars Sales by Country (2027-2032) & (K Units) Table 55. Europe Biologics and Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Europe Biologics and Biosimilars Sales by Country (2021-2026) & (K Units) Table 57. Europe Biologics and Biosimilars Sales by Country (2027-2032) & (K Units) Table 58. Asia Pacific Biologics and Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Asia Pacific Biologics and Biosimilars Sales by Country (2021-2026) & (K Units) Table 60. Asia Pacific Biologics and Biosimilars Sales by Country (2027-2032) & (K Units) Table 61. South America, Middle East and Africa Biologics and Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 62. South America, Middle East and Africa Biologics and Biosimilars Sales by Country (2021-2026) & (K Units) Table 63. South America, Middle East and Africa Biologics and Biosimilars Sales by Country (2027-2032) & (K Units) Table 64. Global Biologics and Biosimilars Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 65. Global Biologics and Biosimilars Revenue by Region (2021-2026) & (US$ Million) Table 66. Global Biologics and Biosimilars Revenue by Region (2027-2032) & (US$ Million) Table 67. Global Biologics and Biosimilars Revenue Market Share by Region (2021-2026) Table 68. Global Biologics and Biosimilars Revenue Market Share by Region (2027-2032) Table 69. Roche Company Information Table 70. Roche Business Overview Table 71. Roche Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Roche Biologics and Biosimilars Product Portfolio Table 73. Roche Recent Development Table 74. Amgen Company Information Table 75. Amgen Business Overview Table 76. Amgen Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Amgen Biologics and Biosimilars Product Portfolio Table 78. Amgen Recent Development Table 79. AbbVie Company Information Table 80. AbbVie Business Overview Table 81. AbbVie Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. AbbVie Biologics and Biosimilars Product Portfolio Table 83. AbbVie Recent Development Table 84. Sanofi-Aventis Company Information Table 85. Sanofi-Aventis Business Overview Table 86. Sanofi-Aventis Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Sanofi-Aventis Biologics and Biosimilars Product Portfolio Table 88. Sanofi-Aventis Recent Development Table 89. Johnson & Johnson Company Information Table 90. Johnson & Johnson Business Overview Table 91. Johnson & Johnson Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Johnson & Johnson Biologics and Biosimilars Product Portfolio Table 93. Johnson & Johnson Recent Development Table 94. Pfizer Company Information Table 95. Pfizer Business Overview Table 96. Pfizer Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Pfizer Biologics and Biosimilars Product Portfolio Table 98. Pfizer Recent Development Table 99. Novo Nordisk Company Information Table 100. Novo Nordisk Business Overview Table 101. Novo Nordisk Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Novo Nordisk Biologics and Biosimilars Product Portfolio Table 103. Novo Nordisk Recent Development Table 104. Eli Lilly Company Information Table 105. Eli Lilly Business Overview Table 106. Eli Lilly Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Eli Lilly Biologics and Biosimilars Product Portfolio Table 108. Eli Lilly Recent Development Table 109. Novartis Company Information Table 110. Novartis Business Overview Table 111. Novartis Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Novartis Biologics and Biosimilars Product Portfolio Table 113. Novartis Recent Development Table 114. Merck Company Information Table 115. Merck Business Overview Table 116. Merck Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Merck Biologics and Biosimilars Product Portfolio Table 118. Merck Recent Development Table 119. 3sbio Company Information Table 120. 3sbio Business Overview Table 121. 3sbio Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. 3sbio Biologics and Biosimilars Product Portfolio Table 123. 3sbio Recent Development Table 124. Changchun High Tech Company Information Table 125. Changchun High Tech Business Overview Table 126. Changchun High Tech Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Changchun High Tech Biologics and Biosimilars Product Portfolio Table 128. Changchun High Tech Recent Development Table 129. CP Guojian Company Information Table 130. CP Guojian Business Overview Table 131. CP Guojian Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. CP Guojian Biologics and Biosimilars Product Portfolio Table 133. CP Guojian Recent Development Table 134. Biotech Company Information Table 135. Biotech Business Overview Table 136. Biotech Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. Biotech Biologics and Biosimilars Product Portfolio Table 138. Biotech Recent Development Table 139. Gelgen Company Information Table 140. Gelgen Business Overview Table 141. Gelgen Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 142. Gelgen Biologics and Biosimilars Product Portfolio Table 143. Gelgen Recent Development Table 144. Innovent Company Information Table 145. Innovent Business Overview Table 146. Innovent Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 147. Innovent Biologics and Biosimilars Product Portfolio Table 148. Innovent Recent Development Table 149. Dong Bao Company Information Table 150. Dong Bao Business Overview Table 151. Dong Bao Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 152. Dong Bao Biologics and Biosimilars Product Portfolio Table 153. Dong Bao Recent Development Table 154. Ganlee Company Information Table 155. Ganlee Business Overview Table 156. Ganlee Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 157. Ganlee Biologics and Biosimilars Product Portfolio Table 158. Ganlee Recent Development Table 159. United Laboratories Company Information Table 160. United Laboratories Business Overview Table 161. United Laboratories Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 162. United Laboratories Biologics and Biosimilars Product Portfolio Table 163. United Laboratories Recent Development Table 164. Key Raw Materials Table 165. Raw Materials Key Suppliers Table 166. Biologics and Biosimilars Distributors List Table 167. Biologics and Biosimilars Customers List Table 168. Research Programs/Design for This Report Table 169. Authors List of This Report Table 170. Secondary Sources Table 171. Primary Sources List of Figures Figure 1. Biologics and Biosimilars Product Image Figure 2. Global Biologics and Biosimilars Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 4. Global Biologics and Biosimilars Sales (2021-2032) & (K Units) Figure 5. Global Biologics and Biosimilars Average Price (USD/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Biologics and Biosimilars Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Monoclonal Antibodies Image Figure 9. Interferon Image Figure 10. Erythropoietin Image Figure 11. Insulin Image Figure 12. Vaccines Image Figure 13. Others Image Figure 14. Global Biologics and Biosimilars Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Biologics and Biosimilars Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Biologics and Biosimilars Sales Market Share by Type (2021-2032) Figure 17. Global Biologics and Biosimilars Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global Biologics and Biosimilars Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Biologics and Biosimilars Revenue Market Share by Type (2021-2032) Figure 20. Tumor Image Figure 21. Diabetes Image Figure 22. Cardiovascular Image Figure 23. Hemophilia Image Figure 24. Others Image Figure 25. Global Biologics and Biosimilars Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Biologics and Biosimilars Sales Market Share 2021 VS 2025 VS 2032 Figure 27. Global Biologics and Biosimilars Sales Market Share by Application (2021-2032) Figure 28. Global Biologics and Biosimilars Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 29. Global Biologics and Biosimilars Revenue Market Share 2021 VS 2025 VS 2032 Figure 30. Global Biologics and Biosimilars Revenue Market Share by Application (2021-2032) Figure 31. North America Biologics and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 32. North America Biologics and Biosimilars Sales Market Share by Country (2021-2032) Figure 33. U.S. Biologics and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Canada Biologics and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Mexico Biologics and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe Biologics and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Europe Biologics and Biosimilars Sales Market Share by Country (2021-2032) Figure 38. Germany Biologics and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 39. France Biologics and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 40. U.K. Biologics and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Italy Biologics and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Netherlands Biologics and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific Biologics and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Asia Pacific Biologics and Biosimilars Sales Market Share by Country (2021-2032) Figure 45. China Biologics and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Japan Biologics and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South Korea Biologics and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Southeast Asia Biologics and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 49. India Biologics and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Australia Biologics and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa Biologics and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South America, Middle East and Africa Biologics and Biosimilars Sales Market Share by Country (2021-2032) Figure 53. Brazil Biologics and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 54. South Africa Biologics and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Saudi Arabia Biologics and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Turkey Biologics and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Argentina Biologics and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 58. UAE Biologics and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Egypt Biologics and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Chile Biologics and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 61. Global Biologics and Biosimilars Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Global Biologics and Biosimilars Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 63. North America Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Figure 64. North America Biologics and Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Europe Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Figure 66. Europe Biologics and Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Asia-Pacific Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Figure 68. Asia-Pacific Biologics and Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. South America, Middle East and Africa Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Figure 70. South America, Middle East and Africa Biologics and Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 71. Biologics and Biosimilars Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Biologics and Biosimilars Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal Antibodies
  • Interferon
  • Erythropoietin
  • Insulin
  • Vaccines
  • Others
Applications
  • Tumor
  • Diabetes
  • Cardiovascular
  • Hemophilia
  • Others
Companies covered
  • Roche
  • Amgen
  • AbbVie
  • Sanofi-Aventis
  • Johnson & Johnson
  • Pfizer
  • Novo Nordisk
  • Eli Lilly
  • Novartis
  • Merck
  • 3sbio
  • Changchun High Tech
  • CP Guojian
  • Biotech
  • Gelgen
  • Innovent
  • Dong Bao
  • Ganlee
  • United Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Biologics and Biosimilars Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Biologics and Biosimilars Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Biologics and Biosimilars Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Biologics and Biosimilars Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Biologics and Biosimilars Market Dynamics
  1. 2.1 Biologics and Biosimilars Industry Trends
  2. 2.2 Biologics and Biosimilars Industry Drivers
  3. 2.3 Biologics and Biosimilars Industry Opportunities and Challenges
  4. 2.4 Biologics and Biosimilars Industry Restraints
3 Biologics and Biosimilars Market by Manufacturers
  1. 3.1 Global Biologics and Biosimilars Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Biologics and Biosimilars Sales by Manufacturers (2021-2026)
  3. 3.3 Global Biologics and Biosimilars Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Biologics and Biosimilars Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Biologics and Biosimilars Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Biologics and Biosimilars Manufacturers, Product Type & Application
  7. 3.7 Global Biologics and Biosimilars Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Biologics and Biosimilars Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Biologics and Biosimilars Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Biologics and Biosimilars Tier 1, Tier 2, and Tier 3
4 Biologics and Biosimilars Market by Type
  1. 4.1 Biologics and Biosimilars Type Introduction
  2. 4.1.1 Monoclonal Antibodies
  3. 4.1.2 Interferon
  4. 4.1.3 Erythropoietin
  5. 4.1.4 Insulin
  6. 4.1.5 Vaccines
  7. 4.1.6 Others
  8. 4.2 Global Biologics and Biosimilars Sales by Type
  9. 4.2.1 Global Biologics and Biosimilars Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Biologics and Biosimilars Sales by Type (2021-2032)
  11. 4.2.3 Global Biologics and Biosimilars Sales Market Share by Type (2021-2032)
  12. 4.3 Global Biologics and Biosimilars Revenue by Type
  13. 4.3.1 Global Biologics and Biosimilars Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Biologics and Biosimilars Revenue by Type (2021-2032)
  15. 4.3.3 Global Biologics and Biosimilars Revenue Market Share by Type (2021-2032)
5 Biologics and Biosimilars Market by Application
  1. 5.1 Biologics and Biosimilars Application Introduction
  2. 5.1.1 Tumor
  3. 5.1.2 Diabetes
  4. 5.1.3 Cardiovascular
  5. 5.1.4 Hemophilia
  6. 5.1.5 Others
  7. 5.2 Global Biologics and Biosimilars Sales by Application
  8. 5.2.1 Global Biologics and Biosimilars Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Biologics and Biosimilars Sales by Application (2021-2032)
  10. 5.2.3 Global Biologics and Biosimilars Sales Market Share by Application (2021-2032)
  11. 5.3 Global Biologics and Biosimilars Revenue by Application
  12. 5.3.1 Global Biologics and Biosimilars Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Biologics and Biosimilars Revenue by Application (2021-2032)
  14. 5.3.3 Global Biologics and Biosimilars Revenue Market Share by Application (2021-2032)
6 Global Biologics and Biosimilars Sales by Region
  1. 6.1 Global Biologics and Biosimilars Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biologics and Biosimilars Sales by Region (2021-2032)
  3. 6.2.1 Global Biologics and Biosimilars Sales by Region (2021-2026)
  4. 6.2.2 Global Biologics and Biosimilars Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Biologics and Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Biologics and Biosimilars Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Biologics and Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Biologics and Biosimilars Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Biologics and Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Biologics and Biosimilars Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Biologics and Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Biologics and Biosimilars Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Biologics and Biosimilars Revenue by Region
  1. 7.1 Global Biologics and Biosimilars Revenue by Region
  2. 7.1.1 Global Biologics and Biosimilars Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Biologics and Biosimilars Revenue by Region (2021-2026)
  4. 7.1.3 Global Biologics and Biosimilars Revenue by Region (2027-2032)
  5. 7.1.4 Global Biologics and Biosimilars Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Biologics and Biosimilars Revenue (2021-2032)
  8. 7.2.2 North America Biologics and Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Biologics and Biosimilars Revenue (2021-2032)
  11. 7.3.2 Europe Biologics and Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Biologics and Biosimilars Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Biologics and Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Biologics and Biosimilars Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Biologics and Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Roche
  2. 8.1.1 Roche Company Information
  3. 8.1.2 Roche Business Overview
  4. 8.1.3 Roche Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Roche Biologics and Biosimilars Product Portfolio
  6. 8.1.5 Roche Recent Developments
  7. 8.2 Amgen
  8. 8.2.1 Amgen Company Information
  9. 8.2.2 Amgen Business Overview
  10. 8.2.3 Amgen Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Amgen Biologics and Biosimilars Product Portfolio
  12. 8.2.5 Amgen Recent Developments
  13. 8.3 AbbVie
  14. 8.3.1 AbbVie Company Information
  15. 8.3.2 AbbVie Business Overview
  16. 8.3.3 AbbVie Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 AbbVie Biologics and Biosimilars Product Portfolio
  18. 8.3.5 AbbVie Recent Developments
  19. 8.4 Sanofi-Aventis
  20. 8.4.1 Sanofi-Aventis Company Information
  21. 8.4.2 Sanofi-Aventis Business Overview
  22. 8.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi-Aventis Biologics and Biosimilars Product Portfolio
  24. 8.4.5 Sanofi-Aventis Recent Developments
  25. 8.5 Johnson & Johnson
  26. 8.5.1 Johnson & Johnson Company Information
  27. 8.5.2 Johnson & Johnson Business Overview
  28. 8.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio
  30. 8.5.5 Johnson & Johnson Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Biologics and Biosimilars Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Novo Nordisk
  38. 8.7.1 Novo Nordisk Company Information
  39. 8.7.2 Novo Nordisk Business Overview
  40. 8.7.3 Novo Nordisk Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novo Nordisk Biologics and Biosimilars Product Portfolio
  42. 8.7.5 Novo Nordisk Recent Developments
  43. 8.8 Eli Lilly
  44. 8.8.1 Eli Lilly Company Information
  45. 8.8.2 Eli Lilly Business Overview
  46. 8.8.3 Eli Lilly Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly Biologics and Biosimilars Product Portfolio
  48. 8.8.5 Eli Lilly Recent Developments
  49. 8.9 Novartis
  50. 8.9.1 Novartis Company Information
  51. 8.9.2 Novartis Business Overview
  52. 8.9.3 Novartis Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Novartis Biologics and Biosimilars Product Portfolio
  54. 8.9.5 Novartis Recent Developments
  55. 8.10 Merck
  56. 8.10.1 Merck Company Information
  57. 8.10.2 Merck Business Overview
  58. 8.10.3 Merck Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Merck Biologics and Biosimilars Product Portfolio
  60. 8.10.5 Merck Recent Developments
  61. 8.11 3sbio
  62. 8.11.1 3sbio Company Information
  63. 8.11.2 3sbio Business Overview
  64. 8.11.3 3sbio Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 3sbio Biologics and Biosimilars Product Portfolio
  66. 8.11.5 3sbio Recent Developments
  67. 8.12 Changchun High Tech
  68. 8.12.1 Changchun High Tech Company Information
  69. 8.12.2 Changchun High Tech Business Overview
  70. 8.12.3 Changchun High Tech Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Changchun High Tech Biologics and Biosimilars Product Portfolio
  72. 8.12.5 Changchun High Tech Recent Developments
  73. 8.13 CP Guojian
  74. 8.13.1 CP Guojian Company Information
  75. 8.13.2 CP Guojian Business Overview
  76. 8.13.3 CP Guojian Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 CP Guojian Biologics and Biosimilars Product Portfolio
  78. 8.13.5 CP Guojian Recent Developments
  79. 8.14 Biotech
  80. 8.14.1 Biotech Company Information
  81. 8.14.2 Biotech Business Overview
  82. 8.14.3 Biotech Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Biotech Biologics and Biosimilars Product Portfolio
  84. 8.14.5 Biotech Recent Developments
  85. 8.15 Gelgen
  86. 8.15.1 Gelgen Company Information
  87. 8.15.2 Gelgen Business Overview
  88. 8.15.3 Gelgen Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Gelgen Biologics and Biosimilars Product Portfolio
  90. 8.15.5 Gelgen Recent Developments
  91. 8.16 Innovent
  92. 8.16.1 Innovent Company Information
  93. 8.16.2 Innovent Business Overview
  94. 8.16.3 Innovent Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Innovent Biologics and Biosimilars Product Portfolio
  96. 8.16.5 Innovent Recent Developments
  97. 8.17 Dong Bao
  98. 8.17.1 Dong Bao Company Information
  99. 8.17.2 Dong Bao Business Overview
  100. 8.17.3 Dong Bao Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Dong Bao Biologics and Biosimilars Product Portfolio
  102. 8.17.5 Dong Bao Recent Developments
  103. 8.18 Ganlee
  104. 8.18.1 Ganlee Company Information
  105. 8.18.2 Ganlee Business Overview
  106. 8.18.3 Ganlee Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Ganlee Biologics and Biosimilars Product Portfolio
  108. 8.18.5 Ganlee Recent Developments
  109. 8.19 United Laboratories
  110. 8.19.1 United Laboratories Company Information
  111. 8.19.2 United Laboratories Business Overview
  112. 8.19.3 United Laboratories Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 United Laboratories Biologics and Biosimilars Product Portfolio
  114. 8.19.5 United Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Biologics and Biosimilars Value Chain Analysis
  2. 9.1.1 Biologics and Biosimilars Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Biologics and Biosimilars Production Mode & Process
  6. 9.2 Biologics and Biosimilars Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Biologics and Biosimilars Distributors
  9. 9.2.3 Biologics and Biosimilars Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst